Exact Sciences Marketing Mix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Exact Sciences Bundle
Go Beyond the Snapshot—Get the Full Strategy
Discover how Exact Sciences aligns product innovation, pricing, distribution and promotion to lead in molecular diagnostics—this preview only scratches the surface. Purchase the full 4P's Marketing Mix Analysis for an editable, data-driven report with actionable insights, slides and benchmarking ready for business or academic use.
Product
Noninvasive CRC screening (Cologuard)
Flagship stool-DNA test for detecting colorectal cancer and advanced adenomas in average-risk adults aged 45–84 per USPSTF guidance. It combines DNA biomarkers and hemoglobin with pivotal sensitivity 92.3% for CRC and specificity 86.6%, outperforming FIT sensitivity in trials. Home collection with prepaid return boosts adherence, and ongoing workflow, UI and reporting iterations aim to reduce false positives and improve user experience.
Precision oncology assays (Oncotype DX)
Oncotype DX are genomic assays that inform prognosis and therapy selection in early-stage breast cancer and have prostate and colon applications, delivering recurrence scores that guide chemotherapy and hormone-therapy decisions to reduce overtreatment. Clinically validated with inclusion in NCCN and ASCO guidelines, the assays bolster oncologist confidence. Integrated, patient-facing reports support shared decision-making between clinicians and patients.
Broader oncology diagnostics portfolio
Exact Sciences' broader oncology diagnostics portfolio complements Cologuard (92.1% sensitivity, 86.6% specificity) with MRD, tumor profiling and advanced diagnostics covering the care continuum. The company emphasizes actionable reports to guide therapy selection and is investing in higher sensitivity/specificity and faster turnaround. Its pipeline includes multi-cancer and next-gen screening programs and builds on the 2019 Genomic Health acquisition for scale.
Patient-centric design and services
Exact Sciences designs a patient-centric end-to-end experience—clear instructions, multilingual support and automated reminders—to reduce friction; telephonic and digital assistance lift correct kit completion and educational materials demystify genomics (Cologuard clinical sensitivity for colorectal cancer 92% and specificity 87%, NEJM 2014), while accessibility features and caregiver support raise completion across populations.
- Kit return improvement: reminder programs can increase returns up to 20%
- Clinical sensitivity: colorectal cancer 92%
- Specificity: 87%
- Multilingual and caregiver outreach boost equity in completion
Clinician-first reporting and integration
Clinician-first reports are standardized, concise, and integrated with major EHRs (Epic, Cerner) to streamline workflows; decision aids and USPSTF/ACS guideline references are embedded to speed interpretation. Dedicated medical affairs and case consultation teams support complex cases, while ongoing provider feedback loops (active in 2024) drive iterative product refinements.
- EHR integration: Epic, Cerner
- Guideline-linked: USPSTF, ACS
- Dedicated medical affairs support
- Continuous provider feedback (2024)
Stool-DNA: 92.3%/86.6% CRC, 20% return
Cologuard flagship stool-DNA screening for average-risk adults (USPSTF-aligned), clinical sensitivity ~92.3% for CRC and specificity ~86.6%, home kit with prepaid return and reminders raising adherence; oncology portfolio (Oncotype DX, MRD, profiling) supports guideline-driven care and integrated EHR reporting. Continuous 2024 provider feedback informs product iteration.
| Metric | Value |
|---|---|
| CRC sensitivity | 92.3% |
| Specificity | 86.6% |
| Kit return uplift | up to 20% |
What is included in the product
Detailed Word Document
Delivers a professionally written, company-specific deep dive into Exact Sciences' Product, Price, Place, and Promotion strategies. Ideal for managers, consultants, and marketers needing a grounded, example-driven breakdown of Exact Sciences' market positioning, competitive context, and strategic implications—ready to repurpose for reports or presentations.
Customizable Excel Spreadsheet
Condenses Exact Sciences’ 4Ps into a high-level, at-a-glance view that relieves analysis overload for leadership and cross‑functional teams; easily customizable for presentations, competitive comparisons, or rapid marketing planning to align strategy and accelerate decision-making.
Place
Provider-driven distribution
Cologuard and Exact Sciences precision tests are ordered by physicians, advanced practitioners and health systems as part of standard care pathways, with dedicated sales and medical teams targeting oncology, primary care and GI channels. Embedded ordering within EHRs and patient portals reduces friction at the point of care and increases adherence to screening workflows. Hospital laboratories and specialty clinics serve as primary access nodes for specimen collection and logistics.
At-home kit logistics
Cologuard kits are shipped directly to patients with prepaid returns to Exact Sciences centralized labs in Madison, WI, supporting a program used by over 6 million patients since launch. Automated reminders and end-to-end tracking improve collection rates and reduce lost samples. Robust stabilization chemistry and controlled shipping protect biomarker integrity. Scalable fulfillment handles national screening campaigns and seasonal spikes of hundreds of thousands of kits.
Central and partner laboratory networks
Testing is performed in CLIA-certified, CAP-accredited central labs to ensure quality and consistency; capacity planning balances turnaround time with peak volumes while maintaining compliance. Select partnerships extend reach into international markets and specialized assays, and integrated data connectivity delivers rapid electronic reports back to providers.
Payer and health system integration
Exact Sciences secures in-network agreements with major commercial plans, Medicare (coverage since 2014), and Medicaid to broaden Cologuard access; payer care-gap programs and ACO partnerships embed screening into population-health workflows. Health system contracts standardize ordering, pricing, and performance metrics, while coverage policies place testing within preventive care benefits.
- Medicare coverage: MolDx decision 2014
- ACO/care-gap integration: embeds screening into workflows
- Contracts: standardize orders, pricing, metrics
- Coverage policies: drive preventive-care placement
Digital channels and patient portals
Population screening: 6,000,000+ tested, mailed kits ~65% completion
Place: Cologuard distributes via physician orders, EHR-embedded workflows and direct-to-patient mailed kits (over 6 million patients tested since launch), with centralized CLIA/CAP labs in Madison, WI and national fulfillment handling seasonal spikes. Mailed kit completion ~65%; Medicare coverage since MolDx decision 2014; payer and ACO contracts embed screening in population-health pathways.
| Metric | Value |
|---|---|
| Patients tested | >6,000,000 |
| Kit completion | ~65% |
| Lab | CLIA/CAP Madison, WI |
| Medicare | Coverage since 2014 |
What You Preview Is What You Download
Exact Sciences 4P's Marketing Mix Analysis
The Exact Sciences 4P's Marketing Mix Analysis shown here is the exact, fully finished document you’ll receive immediately after purchase—no samples or mockups. It’s a complete, editable marketing mix ready for use in strategy, presentations, or reporting. Buy with confidence knowing the preview equals the final deliverable.
Promotion
Guideline-aligned clinical education
Medical affairs drive guideline-aligned education highlighting Oncotype DX data (TAILORx n=10,273) and Cologuard performance (sensitivity 92.3%, specificity 86.6%), supported by over 600 peer-reviewed publications and inclusion in ASCO/NCCN guidance. CME, grand rounds and congress presence (ASCO/ESMO) build credibility, while KOL-led peer-to-peer forums tackle real-world nuances and health-economic analyses reinforce value propositions.
Population health and payer campaigns
Co-branded Exact Sciences–insurer campaigns close care gaps tied to HEDIS/STAR measures—colorectal screening is a HEDIS metric and Medicare Advantage quality bonuses can add up to 5% to plan benchmarks. Stratified outreach nudges eligible members to complete screening, while provider dashboards flag panels overdue for tests. ROI storytelling emphasizes avoided late-stage colorectal cancer costs and uplift in quality scores; colorectal cancer remains the third leading cause of cancer death in the US.
Consumer awareness and adherence nudges
Direct-to-consumer messaging highlights Cologuard noninvasive ease to address the US colorectal screening gap (CDC: ~67% up-to-date in 2020), while SMS, email and mail reminders have been shown to boost kit completion by as much as 15–20 percentage points post-order; culturally tailored materials can raise uptake in underserved groups by ~10 percentage points, and clear calls-to-action steer patients to discuss screening with providers.
Health system partnerships and co-marketing
- Partnerships: integrated into wellness workflows
- EHR prompts: +20–30% orders
- Completion rates: +10–25%
- Time-to-result: −3–7 days
- Metrics: completion, time-to-result, diagnostic yield
Value and outcomes communication
Messaging highlights early detection (Cologuard sensitivity for colorectal cancer 92.2% and specificity 86.6 per NEJM 2014), therapy optimization, and reduced overtreatment; Exact Sciences cites real-world studies and payer budget-impact models supporting adoption and QoL gains. Clinician and patient testimonials humanize benefits while transparent performance metrics (published sensitivity/specificity, real-world uptake) build stakeholder trust.
- early-detection: sensitivity 92.2%
- specificity: 86.6%
- real-world evidence: increased screening uptake (company-published)
- budget-impact models: support payer adoption
- testimonials + transparent metrics: trust
Increase CRC screening: EHR +20-30%, reminders +15-20 pp, sens 92.2%
Promotion leverages medical affairs, KOLs, DTC and payer co-branded campaigns to drive Cologuard uptake (sensitivity 92.2%, specificity 86.6%), close HEDIS/MA care gaps (MA bonuses up to ~5%), and uses EHR prompts (+20–30% orders), reminders (+15–20 pp completion) and cultural tailoring (+~10 pp) to raise screening from CDC baseline ~67% (2020).
| Metric | Value |
|---|---|
| Sensitivity | 92.2% |
| Specificity | 86.6% |
| EHR uplift | +20–30% |
| Reminder impact | +15–20 pp |
Price
Value-based pricing and reimbursement
Pricing emphasizes clinical utility—Cologuard sensitivity 92.3% and specificity 86.6% from pivotal data—plus modeled downstream cost savings in screening pathways. Broad Medicare and commercial coverage limits out-of-pocket exposure, with average Medicare reimbursement near $500. Coding and prior-authorization support streamline claims, while payer negotiations are underpinned by health-economic dossiers and CER.
Tiered and contracted rates
Exact Sciences uses tiered, contracted rates with Cologuard list price at about 649 USD while offering volume-based discounts to health systems, ACOs and payers. Pricing is differentiated by assay complexity and service tiers, and multi-year (commonly 3–5 year) contracts lock in predictable costs and service KPIs. International pricing is adjusted to local reimbursement frameworks.
Patient affordability programs
Exact Sciences offers patient affordability programs including financial assistance and payment plans to mitigate cost barriers for underinsured patients; Cologuard's commonly cited list price is 649 USD, prompting these support measures. Transparent pricing estimates are provided pre-test when possible, and caps on patient responsibility help support adherence to recommended screening schedules. Outreach efforts educate patients on coverage and assistance options.
Bundled and pathway-aligned offers
Bundled pricing aligns with care pathways by pairing Cologuard screening with negotiated follow-up services, reducing administrative friction and total cost of ownership; Exact Sciences reported $2.19 billion revenue in 2023, driven largely by screening adoption. Integrated oncology solutions can include multiple assays at discounted, volume-based rates, while programmatic pricing ties reimbursement to population health goals and completion targets to improve adherence.
- Pathway bundles: screening + follow-up
- Integrated assays: negotiated volume rates
- Programmatic pricing: linked to completion targets
- Benefit: lower administrative friction and TCO
Outcome and performance-linked models
High-sensitivity stool test: 92.3% sensitivity, 86.6% specificity; list $649, Medicare ~$500
Pricing emphasizes clinical value and downstream savings—Cologuard sensitivity 92.3%/specificity 86.6%—with list price 649 USD and average Medicare reimbursement ~500 USD. Broad coverage, patient assistance and bundled/programmatic contracts (shared-savings pilots) lower OOP and tie fees to completion/turnaround KPIs; FY2024 revenue ~3.3B supports negotiation scale.
| Metric | Value |
|---|---|
| List price | 649 USD |
| Medicare avg reimb | ~500 USD |
| Sensitivity / Specificity | 92.3% / 86.6% |
| FY2024 revenue | ~3.3B USD |